NIAMRRE  Welcomes Genvax Technologies as a New Member

Prevention and Treatment of Animal Diseases to Benefit One Health

AMES, IOWA (August 20, 2021) — The National Institute of Antimicrobial Resistance Research and Education (NIAMRRE), a member organization that drives cross-sector engagement and coordinated action to address the global threat of antimicrobial resistance (AMR), today announced Genvax Technologies as a new member.

“Genvax Technologies is dedicated to cultivating new ideas to develop solutions that create long-lasting impacts on animal health worldwide,” said Executive Director, Dr. Paul Plummer. “Their focus on novel vaccines to prevent and treat animal diseases aligns with NIAMRRE’s focus on addressing AMR using the One Health approach—achieving optimal health outcomes between people, animals, plants, and our shared environment.”

A startup vaccine company, Genvax Technologies develops next-generation mRNA plus nanoparticle vaccines. This new type of vaccine helps protect against infectious diseases by teaching cells how to make a protein to trigger an immune response inside the body; in addition, the composition of these novel vaccines aid in targeted delivery while simultaneously improving their efficacy.

“Vaccines are a critical tool for livestock producers in the face of endemic and emerging infectious diseases,” said Joel Harris, CEO, and Co-founder of Genvax Technologies. “There is a great need for rapid-response vaccines in combination with the reduction of antibiotic use.”

“Reducing antibiotic use in human and animal health is part of the focus of the National Action Plan for Combating Antibiotic-Resistant Bacteria,” said Dr. Plummer. “Preventing infectious diseases through effective vaccination is an important strategy for helping to reduce the need for antibiotics, and we are excited to add Genvax Technologies to our member roster.”

Genvax Technologies joins NIAMRRE’s diverse membership roster that represents academic institutions, commodity groups, pharma and health organizations, retailers, nonprofits and member associations, and startup companies. Organizations committed to cross-sector engagement to stop the spread of AMR may apply for membership. Members are accepted year-round for organizations dedicated to advancing the One Health approach—a collaborative methodology to achieve optimal health outcomes between people, animals, plants, and their shared environment.

To find out more about Genvax Technologies, visit



The National Institute of Antimicrobial Resistance Research and Education provides local, national, and international leadership in combating antimicrobial resistance (AMR). Based at the Iowa State University Research Park, in Ames, Iowa, NIAMRRE drives collaborative and integrative research, education, and engagement to solve AMR challenges and benefit society using a One Health approach. For more information, visit and follow us on Facebook, LinkedIn, and Twitter.


Genvax Technologies is a startup animal vaccine company located in Ames, Iowa. We have a dynamic team of experienced scientists and entrepreneurs poised to develop next generation mRNA + nanoparticle vaccines. We are focused on developing novel vaccines for the prevention and treatment of animal diseases. We cultivate new ideas to make our world a better place and strive to create a long-lasting impact on animal health world-wide.


Jazzy McCroskey, MA
Communications and Integrated Marketing Lead

Genvax Technologies
Joel Harris, BA, PBD
CEO and Co-Founder